Pfizer stops distribution of Anti Smoking Drug

The drugmaker is recalling a number of anti-smoking drugs.


Last Updated on June 28, 2021 by The Health Master

Pfizer Inc said recently that it is pausing the distribution of its anti-smoking treatment, Chantix, after finding elevated levels of cancer-causing agents called nitrosamines in the pills.

The drugmaker is recalling a number of anti-smoking drugs. The US drug regulator has, in the past, reached out to companies whose drugs had N-nitrosodimethylamine (NDMA) over accepted levels.

Picture: Pixabay

The US Food and Drug Administration (USFDA) last year found high levels of NDMA in some versions of the popular diabetes drug metformin. NDMA contamination was responsible for the recall of the heartburn drug Zantac sold by Sanofi SA in 2019.

Chantix was approved by the USFDA in May 2006 as a prescription medication that, along with support, helps adults aged 18 and over quit smoking and is used for 12 to 24 weeks.

Pfizer said the pause in distribution is out of an abundance of caution and pending further testing.

“The benefits of Chantix outweigh the very low potential risks, if any, posed by nitrosamine exposure from varenicline on top of other common sources over a lifetime,” Pfizer spokesperson Steven Danehy said in an email to Reuters.

Dr Reddy’s recalls 2,980 bottles of Atorvastatin Calcium tablets

Sun Pharma recalls 50,868 bottles of diabetes drug in US

Lupin, Sun, Jubilant recall generic medicines in US

Sun Pharma, Alembic recall products in the US market

Zydus Cadila, Alembic Pharma recall these 2 drugs in US

Pharma Companies recall these drugs in US

Copyright – An article (Part-1)

PCI releases draft syllabus for Diploma in Pharmacy

IPCA Lab gets CDSCO nod to conduct Phase-III study of HCQ

DCGI allows to conduct phase-III clinical trials on C-19 drug

Mankind, BDR Pharma to distribute Baricitinib in India

IPC to sensitize stakeholders on manufacturing of Quality Drugs


Enter your email address:

Delivered by FeedBurner